Microbix Biosystems (MBX) Stock Price, News & Analysis

Company Overview

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: C$0.47 to C$0.50
• 50-Day Range: C$0.30 to C$0.52
• 52-Week Range: C$0.29 to C$0.52
• Volume: 190,859 shs
• Average Volume: 279,751 shs
• Market Capitalization: C$64.25 million
• P/E Ratio: 11.75
• Dividend Yield: 2.30%
• Price Target: N/A
• Consensus Rating: N/A

MBX Stock Analysis - Frequently Asked Questions

How have MBX shares performed this year?

Microbix Biosystems' stock was trading at C$0.41 on January 1st, 2025. Since then, MBX shares have increased by 14.6% and is now trading at C$0.47.
View the best growth stocks for 2025 here.

How do I buy shares of Microbix Biosystems?

Shares of MBX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Microbix Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Microbix Biosystems investors own include TransAlta Renewables (RNW), Moderna (MRNA), Canopy Growth (CGC), NightHawk Biosciences (NHWK), Organigram (OGI), VEON (VEON) and Vaxart (VXRT).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:MBX
• CUSIP: N/A
• CIK: N/A
• Web: microbix.com
• Phone: +1-905-3618910
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C$0.04
• Trailing P/E Ratio: 11.75
• Forward P/E Ratio: 23.50
• P/E Growth: N/A
• Net Income: C$5.08 million
• Net Margins: 21.73%
• Pretax Margin: N/A
• Return on Equity: 20.04%
• Return on Assets: 3.82%

Debt

• Debt-to-Equity Ratio: 22.68
• Current Ratio: 6.62
• Quick Ratio: 5.57

Sales & Book Value

• Annual Sales: C$23.36 million
• Price / Sales: 2.75
• Cash Flow: C$0.11 per share
• Price / Cash Flow: 4.13
• Book Value: C$0.20 per share
• Price / Book: 2.35

Miscellaneous

• Outstanding Shares: 136,700,000
• Free Float: N/A
• Market Cap: C$64.25 million
• Optionable: Not Optionable
• Beta: 0.34